About this guideline

About this guideline

The following recommendations have been taken from the previous NICE clinical guideline 23 'Management of depression in primary and secondary care'. Note that the evidence for these recommendations has not been updated. Any wording changes have been made for clarification only.

Recommendation number in updated NICE clinical guideline 90

Recommendation number in NICE clinical guideline 23

1.1.1.2

1.1.2.1/1.1.3.1/1.1.3.2

1.1.1.3

1.1.2.3

1.1.1.4

1.1.2.2

1.1.4.6

1.1.6.4/1.1.6.6

1.1.5.2

1.1.3.3

1.3.2.1

1.5.1.1

1.3.2.3

1.1.6.5

1.3.2.4

1.5.2.6/1.5.2.7

1.4.1.1

1.1.1.1

1.4.1.2

1.4.1.1

1.4.4.2

1.5.2.37/1.5.2.38

1.5.2.2

1.5.2.13/1.5.2.14

1.5.2.6

1.5.2.10

1.5.2.7

1.5.2.5

1.5.2.9

1.5.2.29

1.6.1.4

1.5.5.3/1.5.5.4

1.8.1.11

1.6.2.14

1.10.1.1

1.6.1.1

1.10.1.2

1.6.1.2

1.10.1.3

1.6.1.3

1.10.2.1

1.7.1.1

1.10.2.3

1.7.1.2

1.10.3.1

1.6.5.1

Recommendations marked [2019] were amended in September 2019 (see Update information). Recommendations marked [amended 2020] were amended in February 2020 to strengthen warnings in line with the 2018 MHRA guidance that valproate must not be used in women and girls of childbearing potential (including young girls who are likely to need treatment into their childbearing years), unless other options are unsuitable and the pregnancy prevention programme is in place.

ISBN: 978-1-4731-2712-8

  • National Institute for Health and Care Excellence (NICE)